Trial Profile

Efficacy and Biomarker exploration of 2nd line Aflibercept in combination with FOLFIRI in advanced colorectal cancer

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 04 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Aflibercept (Primary) ; Fluorouracil (Primary) ; Folinic acid (Primary) ; Irinotecan (Primary)
Indications Adenocarcinoma; Colorectal cancer
Focus Therapeutic Use

Most Recent Events

24 Mar 2021 New source identified and integrated ClinicalTrials.gov: (US National Institutes of Health: NCT04810585).
18 Mar 2021 Planned End Date changed from 5 Feb 2023 to 1 Oct 2025.
18 Mar 2021 Planned primary completion date changed from 5 Feb 2023 to 1 Oct 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com